![Placeholder Image Placeholder Image](https://prod.arctic.novartis.com/sites/novartis_com/files/placeholder.jpeg)
Tags Archive Navigation
icon
-
Media ReleaseNovartis expands targeted radioligand therapy pipeline with in-license for compounds targeting Fibroblast Activation Protein (FAP)
-
Media ReleaseNovartis to unveil new data at ASCO and EHA from its robust portfolio, including overall survival in prostate and breast cancer
-
Media ReleaseNovartis Kisqali® reports longest median overall survival in postmenopausal HR+/HER2- metastatic breast cancer patients
-
Media ReleaseNovartis 177Lu-PSMA-617 significantly improves overall survival and radiographic progression-free survival for men with metastatic castration-resistant prostate cancer in Phase III VISION study
-
Media ReleaseNovartis Kymriah® pivotal trial demonstrates strong response rates and a remarkable safety profile in relapsed or refractory follicular lymphoma
-
Media ReleaseNovartis reports clinically relevant improvement in median overall survival data in final analysis of pivotal NETTER-1 study with targeted radioligand therapy Lutathera
-
Media ReleaseNovartis announces Tabrecta® first published overall survival and updated overall response data in patients with METex14 metastatic NSCLC
-
Media ReleaseNovartis investigational checkpoint inhibitor tislelizumab met primary endpoint of overall survival in pivotal Phase III trial of esophageal cancer after systemic therapy
-
Media ReleaseNovartis Kisqali® data show superior overall survival compared to fulvestrant and consistent efficacy across advanced breast cancer patient subgroups in MONALEESA-3
-
Media ReleaseNovartis announces MET inhibitor capmatinib (INC280), the first potential treatment for METex14 mutated advanced non-small cell lung cancer, granted priority FDA review
-
Media ReleaseNovartis Kymriah® receives FDA Regenerative Medicine Advanced Therapy designation in follicular lymphoma
-
Media ReleaseNovartis data at ASCO and EHA showcase bold approaches to reimagine cancer and blood disorders through multiple therapeutic platforms
Pagination
- ‹ Previous page
- 1
- …
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- › Next page